Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Carcinoma 3Squamous Cell Carcinoma of Head and Neck 2Oligodendroglioma 1Myelodysplastic Syndromes 1Lung Neoplasms 1Hemangioma, Cavernous, Central Nervous System 1Head and Neck Neoplasms 1Glioblastoma 1Cytopenia 1Carcinoma, Squamous Cell 1Carcinoma, Non-Small-Cell Lung 1Astrocytoma 1

Interventions

Cisplatin 76Radiotherapy 44pembrolizumab 39Cetuximab 38Paclitaxel 34Carboplatin 33Docetaxel 30Fluorouracil 25Radiotherapy, Intensity-Modulated 22Nivolumab 18Drug Therapy 14Radiation 12Erlotinib Hydrochloride 9cemiplimab 8Magnetic Resonance Spectroscopy 8130-nm albumin-bound paclitaxel 8durvalumab 7atezolizumab 7Cyclophosphamide 7Afatinib 7Surgical Procedures, Operative 6Panitumumab 6Leucovorin 6Chemoradiotherapy 6fludarabine 5aldesleukin 5Radiosurgery 5Oxaliplatin 5Methotrexate 5Gemcitabine 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Carcinoma, Squamous Cell × DNA × Clear all
NCT02211027 2017-09-07

Biological Vaccine: Semi-allogeneic Human Fibroblasts (MRC-5) Transfected With DNA

University of Pittsburgh

Phase 1 Withdrawn
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Carcinoma, Squamous Cell, Head and Neck Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡